AKT1 and lung cancer: The higher basal levels of p-Akt in lung cancer cell lines, and associated similar cytotoxicity between the targeted drug combination and a targeted formulation containing DXR alone, suggested the requirement of a higher dose of the sphingolipid than the one delivered, to enable an advantage of the former formulation.